Comparing blood thinners after a heart attack
Part of Heart & circulation clinical trials.
This study compares two ways to lower the chances of another heart attack: taking the standard medicine (clopidogrel) versus taking a combination of aspirin and a lower dose of a blood thinner (rivaroxaban). If you join, you'll be assigned to one of these options to see which works better for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 65 years old and had a heart attack at least a year ago.
- You have heart disease or peripheral artery disease (blocked arteries).
- You have not had a major bleeding problem or an allergy to aspirin or clopidogrel.
- Your kidneys and liver work well enough (no severe kidney or liver disease).
- You are not taking certain other blood thinners or other trial medicines that can interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.
This trial tests whether taking just one blood thinner (clopidogrel) is as safe and effective as taking two (clopidogrel plus aspirin) for older adults or people at high bleeding risk who have had a drug-coated balloon procedure to open blocked heart arteries.
This study compares two blood-thinning medicines to see which works better for people who have both atrial fibrillation (irregular heartbeat) and heart disease. It aims to reduce the risk of heart attack or stroke while avoiding bleeding problems.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This study tests whether a common blood thinner (apixaban) alone is as safe and effective as combining it with another drug (clopidogrel) to prevent future strokes in people who have both atrial fibrillation and narrowing in the arteries leading to the brain. It aims to find the best way to reduce stroke risk while minimizing bleeding.
This study tests two different blood-thinning medicines to see which is better at preventing another stroke in people who recently had a stroke with no clear cause. The goal is to find a treatment that works well and is safe for you.
Hear when a new Cardiac Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.